SCHEMBL1647584

SCHEMBL1647584

CO[C@H]1O[C@H](COCc2ccccc2)[C@@H](O[C@@H]2O[C@H]3COC(C)(C)O[C@H]3[C@H](OC)[C@H]2O)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SSTR1 P30872 1/20 0.45
▸ SSTR2 P30874 1/20 0.45
▸ SSTR4 P31391 1/20 0.45
▸ SSTR3 P32745 1/20 0.45
▸ SSTR5 P35346 1/20 0.45
▸ GJB2 P29033 4/20 0.44
▸ PTPN1 P18031 4/20 0.40
▸ PTPN2 P17706 3/20 0.40
▸ SLC6A2 P23975 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ NT5E P21589 1/20 0.39
▸ GJA1 P17302 3/20 0.39
▸ PTPN11 Q06124 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1647905 0.93 GJB2 (0.50) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1647937 0.87 NT5E (0.47) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13130004 0.81 GJB2 (0.41) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL10608381 0.80 SSTR1 (0.53) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL6949106 0.79 SSTR1 (0.42) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL8992046 0.78 SSTR1 (0.58) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL10607794 0.78 SSTR1 (0.58) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL10605657 0.78 SSTR1 (0.58) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL10605652 0.78 SSTR1 (0.58) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL8992050 0.78 SSTR1 (0.58) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919614-B2 Disaccharide sequences formed by uronic acid and hexose as to form polysaccharides of 8-24 monosaccharide units whose hydroxyl groups are substituted by alkyl or sulphate groups; possible to modulate activities of glycosaminoglycans type SANOFI-AVENTIS (FR) 2011-04-05 — — US disclosed
US-20040068108-A1 Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them SANOFI-SYNTHELABO (FR) 2004-04-08 — — US disclosed
EP-0904299-B1 SYNTHETIC POLYSACCHARIDES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID POLYSACCHARIDES SANOFI SYNTHELABO (FR) 2001-08-29 — — EP disclosed
EP-0904299-A1 SYNTHETIC POLYSACCHARIDES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID POLYSACCHARIDES SANOFI (FR) 1999-03-31 — — EP disclosed
WO-1997047659-A1 SYNTHETIC POLYSACCHARIDES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID POLYSACCHARIDES SANOFI (FR) 1997-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068108-A1 Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them UGGT1, GALE, UGDH SSTR1 881/4885SSTR2 1195/4885SSTR4 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback